Ponatinib

證據等級: L5

預測適應症: 2 個

Ponatinib: From Unspecified Original Indication to Gingival Fibromatosis

One-Sentence Summary

Ponatinib's original approved indication and mechanism of action are not available in the current data set (both flagged as data gaps). The TxGNN model predicts it may be effective for Gingival Fibromatosis, but this prediction is currently supported by 0 clinical trials and 0 publications — evidence level L5 (model prediction only).

Quick Overview

Item	Content
Original Indication	Not available (no license or indication data on file)
Predicted New Indication	Fibromatosis, gingival
TxGNN Prediction Score	99.04%
Evidence Level	L5
Norway Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for ponatinib is not on file (flagged as a High-severity data gap). However, the evidence pack's own repurposing rationale identifies ponatinib as a multi-kinase inhibitor targeting BCR-ABL, FGFR, PDGFR, VEGFR, KIT, and SRC — consistent with its known class as a tyrosine kinase inhibitor.

Gingival fibromatosis is mechanistically linked to SOS1/PDGFR signaling and fibroblast overproliferation. Since ponatinib inhibits PDGFR, there is a theoretical basis for suppressing fibroblast proliferation. However, this link is derived purely from the TxGNN score — there is no supporting mechanistic literature, preclinical data, or clinical evidence, and because the original indication data is entirely missing, no credible pharmacological analogy can be drawn between the original and predicted indications.

Given the very weak evidentiary basis (score-only prediction, TxGNN rank 9202 — far outside typical high-confidence ranges), this prediction should be treated as exploratory only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Norway Market Information

Ponatinib is currently not marketed and holds 0 authorizations, so no license/product table is available.

Cytotoxicity

Ponatinib's repurposing rationale identifies it as a multi-kinase inhibitor (BCR-ABL/FGFR/PDGFR/VEGFR/KIT/SRC), consistent with a targeted antineoplastic therapy class, so this section is included for completeness.

Item	Content
Cytotoxicity Classification	Targeted therapy (multi-kinase inhibitor: BCR-ABL/FGFR/PDGFR/VEGFR/KIT/SRC)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. (Regulatory label warnings, contraindications, and DDI data are currently a blocking data gap — see DG001.)

Conclusion and Next Steps

Decision: Hold

Rationale: The top prediction (gingival fibromatosis) is supported only by the TxGNN score, with no clinical trials or literature (L5) and a low prediction rank (9202), and both original-indication and MOA data are missing — insufficient basis to advance. A secondary candidate in the same evidence pack, liposarcoma (score 99.00%, rank 9484), has one preclinical kinase-screening publication (PMID 29132397, L4) suggesting a theoretical kinase-pathway overlap, but it does not test ponatinib directly and is also rated Hold.

To proceed, the following is needed:

TFDA/label warnings and contraindications for ponatinib (DG001, blocking)
Confirmed mechanism of action data from DrugBank (DG002)
Original indication and regulatory history for ponatinib
Mechanistic or preclinical studies directly testing ponatinib in gingival fibromatosis or liposarcoma
If pursuing the liposarcoma signal, targeted validation of ponatinib (not general kinase inhibitors) against liposarcoma cell lines
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.